Overview
Peripheral nerve repair firm's preliminary Q4 revenue rose 21.3%, beating analyst expectations
Company's revenue growth driven by strong product performance and strategic execution
FDA approval of Avance impacted gross margin with one-time costs
Result Drivers
PRODUCT PERFORMANCE - Strong performance across AxoGen's product portfolio drove Q4 revenue growth
STRATEGIC EXECUTION - Improved execution of commercial strategy targeting high-potential accounts contributed to revenue increase
FDA APPROVAL IMPACT - FDA approval of Avance led to one-time costs affecting gross margin
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$59.90 mln
$58 mln (9 Analysts)
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for AxoGen Inc is $36.50, about 8.9% above its January 9 closing price of $33.51
The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 42 three months ago
Press Release: ID:nGNX2Ybtnd
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
